PCOS AND METABOLIC DISORDERS

GISELLE ADRIANA ABRUZZESE; MARIA FLORENCIA HEBER; LEANDRO MARTIN VELEZ; OSCAR LEVALLE; MABEL GRAFFIGNA; SUSANA BELLI; CECILIA GORLA; EDUARDO MORMANDI; PATRICIA OTERO; ALICIA BEATRIZ MOTTA

Chascomus

Jornada; XVI Jornadas Anuales SAB; 2014

Sociedad Argentina de Biologia

Polycystic ovary syndrome (PCOS) is a common disease affecting women in their reproductive age. PCOS is diagnosed by two of these alterations:clinical or biochemical hyperandrogenism, oligo or anovulation and ovarian cysts . PCOS could be classified in two main phenotypes: hyperandrogenic (HA)(with clinical and or  biochemical hyperandrogenism) and no hyperandrogenic (NHA) phenotype. We divided a group of 37 PCOS patients from Hospital Durand into HA and NHA phenotypes and studied the endocrine alterations and the relationship between these phenotypes and the presence of  Metabolic Syndrome(MetS) and cardiovascular risk(CVR).The presence of MetS and CVR were independent of  phenotypes.The HA showed similar levels of triglyceride, HDL and LDL cholesterol, homeostasis index, glycemia, insulin and 17 beta hidroxy steroid dehydrogenase activity as compared with NHA. HA women showed increased levels of total cholesterol and activity of P450 c17 lyase. In the HA group, hyperandrogenemia did not reflect clinical hyperandrogenism found in that patients.  We conclude that hyperandrogenism may be affected by the increase on androgen production and not by the levels of the circulating androgens. We also found that the prevalence of MetS and CVR are independent of the PCOS phenotype.